The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / September / India's TB Labs Face a Capacity Gap
Microbiology & Immunology Infectious Disease Laboratory management Screening and monitoring Molecular Pathology

India’s TB Labs Face a Capacity Gap

Researchers identified gaps in molecular diagnostics, drug susceptibility testing, and treatment monitoring

09/03/2026 News 3 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll
  • Topic Commentary

Share

4 Topic Commentaries

India’s TB Labs Face a Capacity Gap

India’s TB Labs Face a Capacity Gap

  • David W. Dowdy
    David W. Dowdy, MD, PhD

    Tuberculosis epidemiology and diagnostics implementation

    •

    Johns Hopkins Bloomberg School of Public Health

    Microscopic analysis of sputum for TB is cheap and widely available, but misses half of all TB cases," said David Dowdy, MD PhD, lead author of the study and assistant professor in the Department of Epidemiology at the Bloomberg School of Public Health. "TB culture, the current gold standard, requires training and equipment not available in most resource-limited settings. Serological tests are simpler and faster than culture, and are also commercially available in India, so they are an attractive option in theory. However, we found that they are not accurate enough to be useful—after accounting for missed and false-positive TB diagnoses, serological tests cost more and delivered less than either microscopy or culture. Quite simply, serological tests should not be used to diagnose active TB.

    Source
  • David W. Dowdy
    David W. Dowdy, MD, PhD

    Tuberculosis epidemiology and diagnostics implementation

    •

    Johns Hopkins Bloomberg School of Public Health

    The impact of better TB diagnosis depends not only on the accuracy of the test, but also on the behavior of both patients and providers, good access to validated new tools, and quality TB treatment following diagnosis," says the study’s senior author David W. Dowdy, MD, PhD, an assistant professor in the Department of Epidemiology. "To achieve maximum impact of novel diagnostics, India should engage the private sector, improve quality of care across all sectors, and dramatically increase the resources used to fight TB.

    Source
  • Melvin (Mel) Spigelman
    Melvin (Mel) Spigelman, MD

    Tuberculosis drug development and global TB policy

    •

    TB Alliance (Global Alliance for TB Drug Development)

    “Totally resistant tuberculosis is out there, make no mistake,” says Mel Spigelman, chief executive of the TB Alliance in New York. “The reports from India shouldn't come as a surprise to anybody, but it should come as a wake-up call for the world. We need better diagnostics, surveillance and treatment right away.”

    Source
  • Madhukar Pai
    Madhukar Pai, MD, PhD

    Tuberculosis diagnostics and health systems

    •

    McGill University

    “A similar cascade of care analysis to identify critical gaps in the private sector would be most helpful and is urgently needed.”

    Source

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.